middle.news
NeuroScientific Advances StemSmart™ Therapy with Fourth Patient Treatment
9:35am on Tuesday 11th of November, 2025 AEDT
•
Biotechnology
Read Story
NeuroScientific Advances StemSmart™ Therapy with Fourth Patient Treatment
9:35am on Tuesday 11th of November, 2025 AEDT
Key Points
Fourth patient treated under Special Access Scheme for StemSmart™
Real-world data to inform Phase 2 clinical trial design in 2026
Focus on treatment-resistant fistulising Crohn’s disease
Manufacturing and regulatory preparations underway
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neuroscientific Biopharmaceuticals (ASX:NSB)
OPEN ARTICLE